Mitochondrial DNA Plays Pivotal Role in Chemoresistance in Esophageal Cancer

Strategic Insights -

Researchers from Osaka University have made significant progress in understanding the mechanisms behind chemoresistance in esophageal cancer. According to the study, mitochondrial DNA (mtDNA) alterations, including mutations and copy number variations, drive chemoresistance in esophageal cancer. The investigators have identified the role of mtDNA in metabolic reprogramming, epithelial-mesenchymal transition (EMT), and mitochondrial bioenergetics, highlighting the potential for overcoming chemoresistance through novel therapeutic agents and innovative approaches like CRISPR/Cas9 gene editing.

Key Takeaways:

  • Mitochondrial DNA (mtDNA) alterations drive chemoresistance in esophageal cancer, influencing cellular metabolism, oxidative stress regulation, and apoptotic pathways.
  • Specific focus is given to the role of mtDNA in metabolic reprogramming, including its contribution to the Warburg effect and lipid metabolism, as well as its impact on epithelial-mesenchymal transition (EMT) and mitochondrial bioenergetics.
  • Recent advances in targeting mitochondrial pathways through novel therapeutic agents, such as metformin and mitoquinone, are discussed as potential solutions to overcome chemoresistance.
  • The article emphasizes the critical need for continued exploration of mtDNA-targeted therapies to address the unmet needs in EC management and other diseases associated with mitochondria.
  • Koji Tanaka, lead researcher from Osaka University's Departments of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan, is part of the research team.
  • Additional authors for this research include Yasunori Masuike, Yuto Kubo, Takashi Harino, Yukinori Kurokawa, Hidetoshi Eguchi, and Yuichiro Doki.

Statistics:

  • The study was published in December 2025, 15(8):1128, in a special issue of Biomolecules, a journal published by MDPI AG.
  • The research team highlighted the importance of integrating mitochondrial diagnostics with personalized treatment strategies to improve patient outcomes.
  • The World Health Organization estimates that over 500,000 new cases of esophageal cancer are diagnosed worldwide each year.
  • According to the American Cancer Society, there are approximately 16,710 new cases of esophageal cancer diagnosed annually in the United States.

Sources:

  • The Role of Mitochondrial DNA in Modulating Chemoresistance in Esophageal Cancer: Mechanistic Insights and Therapeutic Potential. Biomolecules, 2025, 15(8):1128.
  • Osaka University
  • MDPI AG
  • DOI: https://doi-org.sdpl.idm.oclc.org/10.3390/biom15081128